Avita Medical
1st Floor, Unex House
132-134 Hills Road
Cambridge
CB2 8PA
United Kingdom
Tel: 44-0-1223 341150
Fax: 44-0-1223-341170
Website: http://www.avitamedical.com/
Email: info.eu@avitamedical.com
274 articles about Avita Medical
-
AVITA Medical to Present at TD Cowen 44th Annual Health Care Conference
2/29/2024
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) today announced that David O’Toole, Chief Financial Officer, will present at TD Cowen’s 44th Annual Health Care Conference on Tuesday, March 5, 2024, at 9:50 a.m. Eastern Time.
-
AVITA Medical Submits Response to FDA, Resuming Review Clock for RECELL GO PMA Supplement
2/29/2024
AVITA Medical, Inc. announced it has submitted its response to the U.S. Food and Drug Administration for additional information requested in connection to its premarket approval supplement for RECELL GO™.
-
AVITA Medical Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance
2/22/2024
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today reported financial results for the fourth quarter and full-year ended December 31, 2023.
-
AVITA Medical to Announce Fourth Quarter and Full Year 2023 Financial Results
2/1/2024
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) today announced that it will report its fourth quarter and full year 2023 financial results after the close of the U.S. financial markets on Thursday, February 22, 2024.
-
AVITA Medical Announces Preliminary 2023 Financial Highlights, Provides 2024 Financial Guidance and Business Update
1/10/2024
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”) today announced preliminary unaudited financial highlights for the fourth quarter and full-year 2023, provided financial guidance for the first quarter and full-year 2024, and announced completion of patient enrollment in its post-market study, TONE.
-
AVITA Medical Announces Exclusive Distribution Agreement with Stedical Scientific
1/10/2024
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”) today announced it has entered into an exclusive multi-year distribution agreement with Stedical Scientific, Inc. to commercialize PermeaDerm® Biosynthetic Wound Matrix in the United States.
-
AVITA Medical to Present at the 42nd Annual J.P. Morgan Healthcare Conference
1/4/2024
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices and autologous cellular therapies for skin restoration, today announced that Jim Corbett, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024, at 11:15 a.m. Pacific Time.
-
AVITA Medical to Present at the Piper Sandler 35th Annual Healthcare Conference
11/21/2023
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”) today announced that Jim Corbett, Chief Executive Officer, will present at the Piper Sandler 35th Annual Healthcare Conference in New York on Tuesday, November 28, 2023, at 1:00 p.m. Eastern Time.
-
AVITA Medical Updates Full Year 2023 Guidance
11/20/2023
AVITA Medical, Inc., a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announced an update to its full year 2023 guidance.
-
AVITA Medical Announces Distribution Partnership with PolyMedics Innovations to Expand to Europe
11/9/2023
AVITA Medical, Inc. announced it has entered into a distribution agreement with PolyMedics Innovations GmbH, to strategically expand its global presence to Europe.
-
AVITA Medical Reports Third Quarter Financial Results with 51% Revenue Growth over the Same Period the Prior Year
11/9/2023
AVITA Medical, Inc. reported financial results for the third quarter September 30, 2023.
-
AVITA Medical to Announce Third Quarter 2023 Financial Results
10/19/2023
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced that it will report its third quarter 2023 financial results after the close of the U.S. financial markets on Thursday, November 9, 2023.
-
AVITA Medical Announces Preliminary Third Quarter 2023 Financial Highlights and Secures up to $90 million of Non-Dilutive Debt Financing with OrbiMed to Support Growth Initiatives
10/18/2023
AVITA Medical, Inc. today announced third quarter 2023 financial highlights and the closing of a debt financing facility for up to $90 million with OrbiMed, a healthcare investment firm.
-
AVITA Medical Receives Best Product Award at the American Association for the Surgery of Trauma
9/25/2023
AVITA Medical, Inc. is pleased to announce that the RECELL® System won Best Product for the second year in a row at the Annual Meeting of the American Association for the Surgery of Trauma.
-
AVITA Medical to Present at the Cantor Global Healthcare Conference - September 21, 2023
9/21/2023
AVITA Medical, Inc. announced that Jim Corbett, Chief Executive Officer, will present at the 2023 Cantor Fitzgerald Global Healthcare Conference in New York on Tuesday, September 26, 2023, at 11:05 a.m. Eastern Time.
-
AVITA Medical to Participate in Upcoming Investor Conferences
9/6/2023
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced that its management team will participate in the following upcoming investor conferences.
-
AVITA Medical Reports Second Quarter Financial Results
8/10/2023
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today reported financial results for the second quarter June 30, 2023.
-
AVITA Medical to Announce Second Quarter 2023 Financial Results
7/20/2023
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announced today that it will report its second quarter 2023 financial results after the close of the U.S. financial markets on Thursday, August 10, 2023.
-
AVITA Medical Submits FDA PMA Supplement for RECELL GO
6/29/2023
AVITA Medical, Inc. announced its submission of a premarket approval supplement to the U.S. Food and Drug Administration for RECELL GO™.
-
AVITA Medical Rejoins the Russell 3000 Index
6/26/2023
AVITA Medical, Inc. announced that it has rejoined the broad-market Russell 3000® Index following the conclusion of the 2023 Russell indexes annual reconstitution, effective after the U.S. market opens on June 26, 2023.